SELNET clinical practice guidelines for bone sarcoma

Bone sarcoma are infrequent diseases, representing < 0.2% of all adult neoplasms. A multidisciplinary management within reference centers for sarcoma, with discussion of the diagnostic and therapeutic strategies within an expert multidisciplinary tumour board, is essential for these patients, given its heterogeneity and low frequency. This approach leads to an improvement in patient's outcome, as demonstrated in several studies. The Sarcoma European Latin-American Network (SELNET), aims to improve clinical outcome in sarcoma care, with a special focus in Latin-American countries. These Clinical Practice Guidelines (CPG) have been developed and agreed by a multidisciplinary expert group (including medical and radiation oncologist, surgical oncologist, orthopaedic surgeons, radiologist, pathologist, molecular biologist and representatives of patients advocacy groups) of the SELNET consortium, and are conceived to provide the standard approach to diagnosis, treatment and follow-up of bone sarcoma patients in the Latin-American context

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

La renovación de la palabra en el bicentenario de la Argentina : los colores de la mirada lingüística

El libro reúne trabajos en los que se exponen resultados de investigaciones presentadas por investigadores de Argentina, Chile, Brasil, España, Italia y Alemania en el XII Congreso de la Sociedad Argentina de Lingüística (SAL), Bicentenario: la renovación de la palabra, realizado en Mendoza, Argentina, entre el 6 y el 9 de abril de 2010. Las temáticas abordadas en los 167 capítulos muestran las grandes líneas de investigación que se desarrollan fundamentalmente en nuestro país, pero también en los otros países mencionados arriba, y señalan además las áreas que recién se inician, con poca tradición en nuestro país y que deberían fomentarse. Los trabajos aquí publicados se enmarcan dentro de las siguientes disciplinas y/o campos de investigación: Fonología, Sintaxis, Semántica y Pragmática, Lingüística Cognitiva, Análisis del Discurso, Psicolingüística, Adquisición de la Lengua, Sociolingüística y Dialectología, Didáctica de la lengua, Lingüística Aplicada, Lingüística Computacional, Historia de la Lengua y la Lingüística, Lenguas Aborígenes, Filosofía del Lenguaje, Lexicología y Terminología

Modelo basado en redes neuronales artificiales para el cálculo de parámetros ambientales en el proceso de curado del tabaco

This paper presents an Artificial Neural Network (ANN) based model for environmental variables related to the tobacco drying process. A fitting ANN was used to estimate and predict temperature and relative humidity inside the tobacco dryer: the estimation consists of calculating the value of these variables in different locations of the dryer and the prediction consists of forecasting the value of these variables with different time horizons. The proposed model has been validated with temperature and relative humidity data obtained from a real tobacco dryer using a Wireless Sensor Network (WSN). On the one hand, an error under 2% was achieved, obtaining temperature as a function of temperature and relative humidity in other locations in the estimation task. Besides, an error around 1.5 times lower than the one obtained with an interpolation method was achieved in the prediction task when the temperature inside the tobacco mass was predicted with time horizons over 2.5 hours as a function of its present and past values. These results show that ANN-based models can be used to improve the tobacco drying process because with these types of models the value of environmental variables can be predicted in the near future and can be estimated in other locations with low errors.Se presenta un modelo basado en Redes Neuronales Artificiales (RNA) para las variables ambientales relativas al proceso de curado de Tabaco. Una RNA de ajuste se empleó para estimar y predecir la temperatura y la humedad relativa en el interior del secadero de tabaco: la estimación consiste en calcular el valor de estas variables en diferentes localizaciones del interior del secadero y la predicción consiste en vaticinar el valor de dichas variables con diferentes horizontes temporales. El modelo propuesto ha sido validado con datos de temperatura y humedad relativa adquiridos de un secadero de tabaco real utilizando una red de sensores inalámbricos (wireless sensor network, WSN). Por una parte, en la etapa de estimación se consiguió un error inferior al 2%, calculando la temperatura en función de la temperatura y la humedad relativa en otros puntos del secadero. Por otra parte, en la etapa de predicción se consiguió un error 1,5 veces inferior al obtenido con un método basado en interpolación, calculando la temperatura futura en el interior de la masa de tabaco con horizontes de predicción superiores a 2,5 horas a partir del valor actual y los valores anteriores de dicha variable. Los resultados muestran que los modelos basados en RNA se pueden utilizar para mejorar el proceso de curado del tabaco porque el valor de las variables ambientales relacionadas se puede predecir en instantes futuros cercanos y se puede estimar en otras localizaciones con errores pequeños utilizando este tipo de modelos